Cybin (OTCMKTS:CYBN – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.01, reports.
Cybin Stock Up 0.2 %
OTCMKTS:CYBN traded up $0.00 on Friday, reaching $0.45. 3,485,328 shares of the company’s stock were exchanged, compared to its average volume of 2,801,353. The firm has a market capitalization of $115.54 million, a price-to-earnings ratio of -2.34 and a beta of 0.90. Cybin has a 52-week low of $0.21 and a 52-week high of $0.74. The business has a fifty day moving average of $0.51 and a 200-day moving average of $0.39.
Hedge Funds Weigh In On Cybin
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Penserra Capital Management LLC boosted its stake in shares of Cybin by 55.8% in the 1st quarter. Penserra Capital Management LLC now owns 407,309 shares of the company’s stock valued at $223,000 after buying an additional 145,929 shares during the period. Jane Street Group LLC grew its holdings in Cybin by 370.6% during the 1st quarter. Jane Street Group LLC now owns 74,631 shares of the company’s stock worth $61,000 after acquiring an additional 58,771 shares in the last quarter. Royal Bank of Canada increased its position in shares of Cybin by 926.4% in the 3rd quarter. Royal Bank of Canada now owns 109,239 shares of the company’s stock valued at $52,000 after purchasing an additional 98,596 shares during the last quarter. Virtu Financial LLC raised its holdings in shares of Cybin by 104.0% in the 4th quarter. Virtu Financial LLC now owns 90,467 shares of the company’s stock valued at $27,000 after purchasing an additional 46,129 shares in the last quarter. Finally, Moneta Group Investment Advisors LLC lifted its position in shares of Cybin by 133,816.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 66,405,251 shares of the company’s stock worth $19,729,000 after purchasing an additional 66,355,664 shares during the last quarter. Hedge funds and other institutional investors own 2.02% of the company’s stock.
Analysts Set New Price Targets
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
- Five stocks we like better than Cybin
- How to Invest in Mining Stocks
- 3 large caps with red hot RSIs with upside
- What Are Dividend Contenders? Investing in Dividend Contenders
- Johnson Controls International: Nothing but upside for investors
- CD Calculator: Certificate of Deposit Calculator
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.